NCT06360250
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Phase: Early Phase 1
Role: Lead Sponsor
Start: Apr 10, 2024
Completion: Oct 30, 2024